Cytokinetics 8-K 2006
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 2, 2006
(Exact name of registrant as specified in its charter)
280 East Grand Avenue
South San Francisco, California 94080
(Address of principal executive offices, including zip code)
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
TABLE OF CONTENTS
ITEM 8.01. OTHER EVENTS.
On October 2, 2006, Cytokinetics, Incorporated issued a press release announcing the presentation of Phase II clinical trial data at the Annual Meeting of the European Society of Medical Oncology for its drug candidates ispinesib (SB-715992) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. This clinical trial was being conducted by the National Cancer Institute. A copy of this press release is being filed with this Current Report on Form 8-K, as Exhibit 99.1, and is hereby incorporated by reference into this Item 8.01.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
The following Exhibit is filed as part of this Current Report on Form 8-K:
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 2, 2006